Here's How The FDA's Temporary Peptide Compounding Policy Impacts Access, Costs And Safety

Overview of the Regulatory Action

The U.S. Food and Drug Administration's evolving approach to peptide compounding has become one of the most closely watched regulatory stories in pharmaceutical law over the past two years. According to a recent report from Blavity News, the agency's temporary policy governing compounded peptides is reshaping how patients access these products, what they pay, and what safety assurances they can expect. While the underlying source article is light on granular detail, the development fits into a broader pattern that regulatory attorneys, compounding pharmacies, and patient advocates have tracked since the GLP-1 shortage era began reshaping the compounding landscape.

At its core, the FDA's temporary posture reflects an attempt to balance two competing pressures: ensuring patient access to therapeutically important peptides during periods of manufacturer shortage, while simultaneously reining in a rapidly expanding market of compounded peptides, many of which have little or no FDA-reviewed safety and efficacy data. This tension is not new, but it has intensified as peptides, ranging from GLP-1 receptor agonists like semaglutide and tirzepatide to lesser-known research compounds such as BPC-157, have surged in popularity through telehealth platforms, wellness clinics, and direct-to-consumer marketing.

Legal Framework and Authority

Compounded drugs occupy a unique legal space distinct from FDA-approved pharmaceuticals. Compounding is governed principally by two provisions of the Federal Food, Drug, and Cosmetic Act (FD&C Act): Section 503A, which applies to traditional pharmacy compounding for individual patients pursuant to a prescription, and Section 503B, which governs outsourcing facilities that may compound in bulk without patient-specific prescriptions but must comply with Current Good Manufacturing Practice (CGMP) standards. Both provisions were substantially amended by the Drug Quality and Security Act (DQSA) of 2013, enacted in the aftermath of the 2012 New England Compounding Center (NECC) fungal meningitis outbreak that killed dozens of patients and sickened hundreds more.

Under both 503A and 503B, compounders may generally only use bulk drug substances that either appear in an FDA-approved drug product, are the subject of a United States Pharmacopeia (USP) or National Formulary (NF) monograph, or appear on an FDA-developed "bulks list." For 503B outsourcing facilities, FDA maintains a formal Category 1, 2, and 3 classification system for substances nominated for the 503B bulk drug substances list, with Category 2 reserved for substances raising significant safety concerns that generally cannot be used in compounding. Several peptides have moved through this nomination and evaluation process in recent years, with FDA placing some on clinical hold or safety-concern categories while reviewing nonclinical and clinical data submitted by sponsors and industry commenters.

Separately, FDA has periodically exercised enforcement discretion, a temporary, non-binding posture that signals the agency will not prioritize enforcement action against certain compounding activity, typically tied to drug shortages listed on FDA's official shortage database. This mechanism was central to the agency's handling of compounded semaglutide and tirzepatide during 2023 and 2024, and it appears to be the operative legal tool underlying the "temporary" peptide policy referenced in the Blavity News report. It is critical to note that enforcement discretion is not a safe harbor created by statute or formal rulemaking; it is a prosecutorial-style policy choice that FDA can narrow, condition, or withdraw with limited notice, as it did when it determined the tirzepatide shortage had resolved.

Industry Implications

For the compounding industry, a temporary policy carries double-edged implications. In the near term, 503A pharmacies and 503B outsourcing facilities that have built business lines around peptide compounding gain continued, if conditional, legal footing to serve patients who cannot access or afford FDA-approved branded alternatives like Ozempic, Wegovy, Mounjaro, or Zepbound. This has mattered enormously for cost and access: compounded versions have often been priced substantially below branded GLP-1 products, which can exceed $1,000 per month without insurance coverage.

At the same time, the temporary and conditional nature of the policy injects significant uncertainty into compounders' business planning. Pharmacies investing in equipment, staffing, and supply chains for peptide production face the risk that FDA could terminate enforcement discretion on short notice, as occurred with tirzepatide. Manufacturers of FDA-approved peptide drugs, meanwhile, have lobbied aggressively against broad compounding allowances, arguing that compounded versions bypass the rigorous safety, efficacy, and manufacturing review required for approved products, and that continued compounding undermines incentives for innovation protected by patent and exclusivity law.

Patient advocacy groups and telehealth companies occupy a middle position, generally supporting continued access for patients with documented shortages or affordability barriers, while expressing concern about quality variability across compounding pharmacies, some of which have faced FDA warning letters or import alerts for sourcing active pharmaceutical ingredients from unregistered foreign facilities.

Compliance Considerations

Compounding pharmacies and outsourcing facilities operating under the temporary policy should pay close attention to several compliance pressure points. First, adherence to patient-specific prescription requirements under 503A remains essential; mass production or marketing that resembles commercial manufacturing can trigger FDA scrutiny regardless of shortage status. Second, 503B facilities must maintain CGMP compliance, including rigorous testing for sterility, potency, and impurity profiles, areas where FDA has previously cited compounders for deficiencies. Third, compounders should monitor FDA's drug shortage database in real time, since enforcement discretion tied to a specific shortage can lapse immediately upon an official shortage resolution determination, as the tirzepatide experience demonstrated. Finally, state boards of pharmacy retain independent authority over 503A compounders, meaning facilities must track both federal and state-level requirements, which do not always move in lockstep.

Looking Ahead

The durability of the FDA's temporary peptide compounding policy remains uncertain, and stakeholders should expect continued volatility. Litigation brought by compounding pharmacy trade groups against FDA's shortage-resolution determinations, ongoing nomination proceedings for peptides on the 503B bulks list, and potential congressional action revisiting the DQSA framework could all alter the landscape in the coming months. As the Blavity News report underscores, patients, providers, and compounders alike are operating in a regulatory environment defined less by settled law than by shifting agency discretion, making close monitoring of FDA guidance, shortage listings, and Federal Register notices essential for anyone participating in this market.